Treatment of canine embolic pulmonary hypertension with recombinant tissue plasminogen activator. Efficacy of dosing regimes. 1988

F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
Department of Medicine, University of Manitoba Health Sciences Centre, Winnipeg, Canada.

We investigated effects of two dosing regimes of recombinant tissue plasminogen activator (rt-PA) and sodium heparin on pulmonary thrombolysis in a canine model of pulmonary hypertension, induced by injection of radioactive blood clots. By continuously counting over both lung fields with a mobile gamma camera, we correlated rate and extent of pulmonary thrombolysis with corresponding pulmonary hemodynamics. Treatment with heparin, over a 3-hour interval, did not result in significant thrombolysis or in a decrease in mean pulmonary artery pressure (PAP). In contrast, rt-PA caused marked pulmonary thrombolysis. While total clot lysis was similar when 1 mg/kg rt-PA was infused over 15 (rt-PA15) or 90 (rt-PA90) minutes (47% and 42%, respectively), rate of lysis during infusion was markedly increased with rt-PA15 (56% vs. 27%/hr, p less than 0.001). Corresponding to the increased rate of thrombolysis with rt-PA15, relative PAP decrease was greater at 15 and 30 minutes. At 4 hours, PAP decreased most with rt-PA90. However, two of the six dogs given rt-PA15 had an increase in PAP and lung radioactivity 1 hour after rt-PA. This was associated with dislodgment of a previously trapped clot. These results suggest that rt-PA may be appropriate therapy for pulmonary embolism and support further studies designed to optimize dosing regimes.

UI MeSH Term Description Entries
D006976 Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES. Pulmonary Hypertension
D010959 Tissue Plasminogen Activator A proteolytic enzyme in the serine protease family found in many tissues which converts PLASMINOGEN to FIBRINOLYSIN. It has fibrin-binding activity and is immunologically different from UROKINASE-TYPE PLASMINOGEN ACTIVATOR. The primary sequence, composed of 527 amino acids, is identical in both the naturally occurring and synthetic proteases. Alteplase,Plasminogen Activator, Tissue-Type,T-Plasminogen Activator,Tissue-Type Plasminogen Activator,Actilyse,Activase,Lysatec rt-PA,TTPA,Tisokinase,Tissue Activator D-44,Lysatec rt PA,Lysatec rtPA,Plasminogen Activator, Tissue,Plasminogen Activator, Tissue Type,T Plasminogen Activator,Tissue Activator D 44,Tissue Type Plasminogen Activator
D011655 Pulmonary Embolism Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS. Pulmonary Thromboembolism,Thromboembolism, Pulmonary,Embolism, Pulmonary,Embolisms, Pulmonary,Pulmonary Embolisms,Pulmonary Thromboembolisms,Thromboembolisms, Pulmonary
D004285 Dogs The domestic dog, Canis familiaris, comprising about 400 breeds, of the carnivore family CANIDAE. They are worldwide in distribution and live in association with people. (Walker's Mammals of the World, 5th ed, p1065) Canis familiaris,Dog
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
March 1989, Neurosurgery,
F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
January 2006, Thrombosis and haemostasis,
F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
July 1992, Annals of neurology,
F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
October 1998, Anesthesiology,
F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
May 2013, BMJ case reports,
F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
August 1995, Thrombosis and haemostasis,
F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
January 2008, Pediatric blood & cancer,
F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
September 1996, Neonatal network : NN,
F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
June 1987, Circulation,
F Shiffman, and J Ducas, and P Hollett, and E Israels, and D Greenberg, and R Cook, and R M Prewitt
October 1988, Presse medicale (Paris, France : 1983),
Copied contents to your clipboard!